Adaptive Randomization of Neratinib in Early Breast Cancer

BACKGROUND: I-SPY2, a standing, multicenter, adaptive phase 2 neoadjuvant trial ongoing in high-risk clinical stage II/III breast cancer, is designed to evaluate multiple, novel experimental agents added to standard chemotherapy for their ability to improve the rate of pathologic complete response (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Park, John W., Liu, Minetta C., Yee, Douglas, Yau, Christina, van 't Veer, Laura J., Symmans, W. Fraser, Paoloni, Melissa, Perlmutter, Jane, Hylton, Nola M., Hogarth, Michael, DeMichele, Angela, Buxton, Meredith B., Chien, A. Jo, Wallace, Anne M., Boughey, Judy C., Haddad, Tufia C., Chui, Stephen Y., Kemmer, Kathleen A., Kaplan, Henry G., Isaacs, Claudine, Nanda, Rita, Tripathy, Debasish, Albain, Kathy S., Edmiston, Kirsten K., Elias, Anthony D., Northfelt, Donald W., Pusztai, Lajos, Moulder, Stacy L., Lang, Julie E., Viscusi, Rebecca K., Euhus, David M., Haley, Barbara B., Khan, Qamar J., Wood, William C., Melisko, Michelle, Schwab, Richard, Lyandres, Julia, Davis, Sarah E., Hirst, Gillian L., Sanil, Ashish, Esserman, Laura J., Berry, Donald A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5259558/
https://ncbi.nlm.nih.gov/pubmed/27406346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513750
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados